Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)

NCT: NCT02984566 · ACTIVE_NOT_RECRUITING

NCT IDNCT02984566
StatusACTIVE_NOT_RECRUITING
Start Date2020-01-14
Completion2026-07

Brief Summary

Primary and secondary liver cancer patients will receive liver SABR with or without KIM intervention.

Frequently Asked Questions

What is Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)?

Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM) is a clinical trial registered under NCT02984566. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT02984566?

The current status of NCT02984566 (Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)) is: ACTIVE_NOT_RECRUITING.

When did Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM) start?

Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM) started on 2020-01-14.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑